The China microarray market is projected to reach $1.62 billion by 2036, at a CAGR of 10.0% from 2026 to 2036, up from an estimated $622.5 million in 2026. The market was valued at $569.0 million in 2025. The growth of this market is primarily fueled by expanding research applications of microarrays, increasing genomics and proteomics research, the rising prevalence of cancers and genetic disorders, and increasing R&D investments by pharma and biotech stakeholders. Additionally, advancements in microarray technologies - including CapitalBio Technology's August 2024 launch of its Chromosome Microarray (CMA) Detection 2.0 chips and Thermo Fisher Scientific's August 2023 launch of a chromosomal microarray to improve cytogenetic research lab productivity - along with the growing adoption of personalized medicine are expected to create substantial growth opportunities for market participants.
The key players operating in the China microarray market are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
The China microarray market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by product, application, and end user.
Among all the products, the Consumables segment is expected to account for the largest share of the China microarray market in 2026. The substantial market share of this segment is due to the increasing incidence of cancer, wide application areas of microarray technology, rising funding for genomic R&D, and growing research for personalized medicine. This segment is also slated to register the highest CAGR during the forecast period, driven by increased volume of testing for chronic diseases and rising awareness among the general population about testing and disease detection.
Among all the applications, the Drug Discovery & Development segment is expected to account for the largest share of the market in 2026, driven by growing public and private investment in pharma and biotech R&D and initiatives by pharmaceutical and biotechnology companies to expand research capabilities. The Research Applications segment, meanwhile, is expected to record the highest CAGR during the forecast period, driven by the high sensitivity of microarray technologies, low sample volume requirements, and cost-effectiveness.
Among all the end users, the Pharmaceutical and Biotechnology Companies segment is expected to account for the largest share of the market in 2026, driven by high pharmaceutical R&D expenditure, rising demand for drug discovery and development, and increasing funding, grants, and investments for genomic research. The Contract Research Organizations (CROs) segment, meanwhile, is projected to record the highest CAGR during the forecast period.
China carries a substantial disease burden supporting this market: according to GLOBOCAN, the number of new cancer cases in China was 4.8 million in 2022, expected to reach 7.1 million by 2045. China also has a high prevalence of congenital disabilities, estimated at nearly 5.6%, with roughly 800,000 to 1,200,000 children found with malformations each year, according to a July 2022 report in the International Journal of Environmental Research and Public Health - a burden the government addresses in part through subsidized screening for 12 types of congenital disabilities.
The key players operating in the China microarray market are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
The China microarray market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by product, application, and end user.
Among all the products, the Consumables segment is expected to account for the largest share of the China microarray market in 2026. The substantial market share of this segment is due to the increasing incidence of cancer, wide application areas of microarray technology, rising funding for genomic R&D, and growing research for personalized medicine. This segment is also slated to register the highest CAGR during the forecast period, driven by increased volume of testing for chronic diseases and rising awareness among the general population about testing and disease detection.
Among all the applications, the Drug Discovery & Development segment is expected to account for the largest share of the market in 2026, driven by growing public and private investment in pharma and biotech R&D and initiatives by pharmaceutical and biotechnology companies to expand research capabilities. The Research Applications segment, meanwhile, is expected to record the highest CAGR during the forecast period, driven by the high sensitivity of microarray technologies, low sample volume requirements, and cost-effectiveness.
Among all the end users, the Pharmaceutical and Biotechnology Companies segment is expected to account for the largest share of the market in 2026, driven by high pharmaceutical R&D expenditure, rising demand for drug discovery and development, and increasing funding, grants, and investments for genomic research. The Contract Research Organizations (CROs) segment, meanwhile, is projected to record the highest CAGR during the forecast period.
China carries a substantial disease burden supporting this market: according to GLOBOCAN, the number of new cancer cases in China was 4.8 million in 2022, expected to reach 7.1 million by 2045. China also has a high prevalence of congenital disabilities, estimated at nearly 5.6%, with roughly 800,000 to 1,200,000 children found with malformations each year, according to a July 2022 report in the International Journal of Environmental Research and Public Health - a burden the government addresses in part through subsidized screening for 12 types of congenital disabilities.
Key Questions Answered in the Report:
- What is the current revenue generated by the China microarray market?
- At what rate is the China microarray market demand projected to grow through 2036?
- What are the historical market sizes and growth rates of the China microarray market?
- What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of product, application, and end user are expected to create major traction for the manufacturers in this market?
- Who are the major players in the China microarray market? What are their specific product offerings in this market?
- What are the recent strategic developments in the China microarray market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. China Microarray Market Assessment — By Product
6. China Microarray Market — By Application
7. China Microarray Market — By End User
8. Competition Analysis
9. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Sino Biological, Inc.
- CapitalBio Technology Co., Ltd.
- Arrayit Corporation
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Revvity, Inc.
- Agilent Technologies, Inc.
- Merck KGaA
- Qiagen N.V.
- RayBiotech Life, Inc. (U.S.).
